MIRA Pharmaceuticals (NASDAQ:MIRA) Issues Earnings Results

MIRA Pharmaceuticals (NASDAQ:MIRA) released its quarterly earnings data on Thursday. The company reported ($0.03) earnings per share for the quarter, FiscalAI reports.

MIRA Pharmaceuticals Stock Performance

Shares of MIRA Pharmaceuticals stock traded down $0.01 during trading hours on Friday, hitting $0.96. The company’s stock had a trading volume of 164,452 shares, compared to its average volume of 137,397. MIRA Pharmaceuticals has a twelve month low of $0.90 and a twelve month high of $2.45. The firm has a fifty day moving average of $1.07 and a 200-day moving average of $1.29.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research note on Friday, March 27th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, MIRA Pharmaceuticals presently has an average rating of “Hold”.

Hedge Funds Weigh In On MIRA Pharmaceuticals

Several large investors have recently modified their holdings of MIRA. XTX Topco Ltd acquired a new position in shares of MIRA Pharmaceuticals in the 2nd quarter valued at $26,000. Creative Planning acquired a new position in MIRA Pharmaceuticals during the 2nd quarter worth about $27,000. Fifth Third Bancorp acquired a new position in MIRA Pharmaceuticals during the 4th quarter worth about $30,000. Two Sigma Investments LP lifted its stake in MIRA Pharmaceuticals by 129.8% during the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock worth $62,000 after acquiring an additional 25,816 shares in the last quarter. Finally, First American Bank lifted its stake in MIRA Pharmaceuticals by 20.0% during the 4th quarter. First American Bank now owns 60,000 shares of the company’s stock worth $91,000 after acquiring an additional 10,000 shares in the last quarter. Institutional investors and hedge funds own 35.16% of the company’s stock.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.